Long-term Outcomes in Patients With Myelin Oligodendrocyte Glycoprotein Immunoglobulin G–Associated Disorder
Open Access
- 1 December 2020
- journal article
- letter
- Published by American Medical Association (AMA) in JAMA Neurology
- Vol. 77 (12) , 1575-1577
Abstract
Data on long-term outcomes of patients with myelin oligodendrocyte glycoprotein (MOG) immunoglobulin G (IgG)–associated disorder (MOGAD) are scarce.1,2 We report outcomes in a single-institution cohort with long-term follow-up.Keywords
This publication has 6 references indexed in Scilit:
- Association of MOG-IgG Serostatus With Relapse After Acute Disseminated Encephalomyelitis and Proposed Diagnostic Criteria for MOG-IgG–Associated DisordersJAMA Neurology, 2018
- Clinical spectrum and prognostic value of CNS MOG autoimmunity in adultsNeurology, 2018
- MOG-IgG in primary and secondary chronic progressive multiple sclerosis: a multicenter study of 200 patients and review of the literatureJournal of Neuroinflammation, 2018
- Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelinationJournal of Neurology, Neurosurgery & Psychiatry, 2017
- Clinical presentation and prognosis in MOG-antibody disease: a UK studyBrain, 2017
- Updated estimate of AQP4-IgG serostatus and disability outcome in neuromyelitis opticaNeurology, 2013